After the European Medicines Agency (EMA) already granted approval for the Johnson & Jonson preparation on Thursday, another piece of good vaccine news follows. As reported by leading newspapers in the German speaking countries, U.S. pharmaceutical company Novavax announced that its vaccine has 96 percent efficacy against the variant of origin of COVID-19.
According to the study conducted in the UK, the efficacy against the British mutation of the virus is said to be ten percent lower. However, how well the drug did against the South African and Brazilian variants was not disclosed. The latest data are expected to accelerate approval of the U.S. vaccine candidate. Novavax expects its vaccine to be approved in the United States as early as May, he said. That’s assuming U.S. authorities are satisfied with the study results so far. Later, the vaccine could also help fight coronavirus in Europe.
Novavax vaccine 96 percent effective, according to study
U.S. pharmaceutical company Novavax announced that its vaccine is 96 percent effective against the original Corona virus and 86 percent effective against the British variant. The company says the figures were obtained within a study Novavax is conducting in the United Kingdom. This brings the company another step closer to approval of the vaccine, it said.
— hpascua/Sources: APA, zdf.de, kleinezeitung.at/picture: aerzteblatt.de
This post has already been read 184 times!